Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2011

View Archived Issues

Rapid eQuIC assay detects abnormal form of prion protein in tissues and bodily fluids

Novel arylindenopyrimidine compound disclosed

Pfizer files application in Japan seeking additional uses of Diflucan

Unigene Laboratories and Cara Therapeutics form agreement for phase I CR-845 trial

Phosphagenics and 3M complete initial formulation of improved oxycodone transdermal patch

Clinical phase III and preclinical data disclosed on antidepressant Lu-AA-21004

Interim phase II/III analysis points to benefits of Urocidin in non-muscle-invasive bladder cancer

Preclinical data support development of MPI-0485520 for rheumatoid arthritis

Otsuka Pharmaceutical presents new vasopressin receptor antagonists

Rivaroxaban is a viable option for secondary stroke prevention in patients with atrial fibrillation

Filgrastim is safe and may reduce lesion size after recent stroke

Pro-Pharmaceuticals changes name to Galectin Therapeutics

Leo Pharma begins phase II trial of LEO-90100 cutaneous spray ointment for psoriasis

XenoPort begins phase III arbaclofen placarbil trial in multiple sclerosis

MediGene and Johns Hopkins to collaborate on development of vaccine candidates from AAVLP program

ReNeuron completes dosing in first cohort of PISCES trial

BioCis Pharma and Lx Therapies combine to form Laurantis Pharma

TetraLogic closes funding round to advance TL-32711

ProteaBio Europe and Mayoly-Spindler's phase I/IIA MS-1819 trial meets expectations

Nuvilex completes acquisition of pancreatic cancer treatment technology

Pharmascience to expand research and development activities with acquisition of Aegera Therapeutics

OncoSec Medical to begin three phase II trials of ElectroImmunotherapy technology in cancer

Cosmo Pharmaceuticals files MAA in E.U. for Budesonide MMX in active ulcerative colitis

Ono Pharmaceutical to pay PAION second milestone payment with start of phase II remimazolam trial

AstraZeneca and Heptares join to discover and develop GPCR-targeting medicines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...